CN105727267B - Recombinant human hyaluronidase freeze-dried preparation and preparation method and application thereof - Google Patents
Recombinant human hyaluronidase freeze-dried preparation and preparation method and application thereof Download PDFInfo
- Publication number
- CN105727267B CN105727267B CN201610081945.XA CN201610081945A CN105727267B CN 105727267 B CN105727267 B CN 105727267B CN 201610081945 A CN201610081945 A CN 201610081945A CN 105727267 B CN105727267 B CN 105727267B
- Authority
- CN
- China
- Prior art keywords
- recombinant human
- human hyaluronidase
- preparation
- hyaluronidase
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 64
- 229940120723 recombinant human hyaluronidase Drugs 0.000 title claims abstract description 50
- 230000000694 effects Effects 0.000 claims abstract description 18
- 102000004190 Enzymes Human genes 0.000 claims abstract description 13
- 108090000790 Enzymes Proteins 0.000 claims abstract description 13
- 229940088598 enzyme Drugs 0.000 claims abstract description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 13
- 239000004094 surface-active agent Substances 0.000 claims abstract description 13
- 239000003223 protective agent Substances 0.000 claims abstract description 6
- 238000007710 freezing Methods 0.000 claims abstract description 5
- 230000008014 freezing Effects 0.000 claims abstract description 5
- 239000006172 buffering agent Substances 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000002577 cryoprotective agent Substances 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000012931 lyophilized formulation Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 6
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical group [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- 239000008215 water for injection Substances 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
- 206010018852 Haematoma Diseases 0.000 claims description 4
- 206010030113 Oedema Diseases 0.000 claims description 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 239000003589 local anesthetic agent Substances 0.000 claims description 4
- 229960005015 local anesthetics Drugs 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 230000008595 infiltration Effects 0.000 claims description 3
- 238000001764 infiltration Methods 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000001201 calcium disodium ethylene diamine tetra-acetate Substances 0.000 claims description 2
- 235000011188 calcium disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 22
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 description 22
- 229960002773 hyaluronidase Drugs 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 8
- 229920002674 hyaluronan Polymers 0.000 description 8
- 229960003160 hyaluronic acid Drugs 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229940044700 hylenex Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 229930195722 L-methionine Natural products 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 230000009102 absorption Effects 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229960004452 methionine Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940054953 vitrase Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108050009363 Hyaluronidases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 229940042450 amphadase Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229940044734 hydase Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960001825 ovine hyaluronidase Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
Abstract
The invention provides a recombinant human hyaluronidase freeze-dried preparation, a preparation method and an application thereof, wherein the recombinant human hyaluronidase freeze-dried preparation is calculated by 10000 counts and comprises the following components: 1400000-500000000 IU of recombinant human hyaluronidase, 5-10 g of buffering agent, 60-180 g of freezing protective agent, 180-300 g of excipient, 5-12 g of enzyme activity protective agent and 0.3-5 g of surfactant.
Description
Technical Field
The invention belongs to the field of preparations, and relates to a recombinant human hyaluronidase freeze-dried preparation, and a preparation method and application thereof.
Background
Hyaluronic Acid (HA), also known as uronic acid, hyaluronic acid or hyaluronic acid, is a linear high molecular glycosaminoglycan composed of two repetitive disaccharide units, D-glucuronic acid and N-acetylglucosamine, widely found in connective tissues, mucus tissues, lens of eyeball and skin of vertebrates, and particularly abundant in tissues such as embryo, cartilage, synovial fluid, vitreous body, umbilical cord, comb, etc. Hyaluronic acid is an acidic mucopolysaccharide widely distributed in human tissue matrixes, and has multiple functions in vivo, such as forming multiple matrixes, limiting the diffusion of water and other extracellular substances, regulating osmotic pressure, regulating the transport of macromolecular substances, forming a physical barrier around cells, and the like. As hyaluronic acid fills between extracellular matrix collagen fibrous scaffolds in vivo by forming a reticulated barrier, subcutaneous diffusion of drug macromolecular species is restricted, the rate of drug arrival at the blood vessel is reduced, and the volume of liquid injected subcutaneously is limited.
Hyaluronidase (also called hyaluronidase) is an endoprotease that specifically hydrolyzes hyaluronic acid and thereby increases the ability of fluid penetration in tissues, and is widely distributed in vivo in tissues and body fluids such as serum, brain, and placenta. Hydrolysis of hyaluronic acid by breaking the gluconic acid bond between glucosamine C1 and glucuronic acid C4 temporarily reduces the viscosity of the intercellular substance, promotes the diffusion of subcutaneous infusion, locally stored exudate or blood, and facilitates absorption.
Hyaluronidase was discovered in 1928, and was named after the 1940 study, which was approved by the FDA in 1948 for marketing in the united states as a spreading agent for use with other drugs. In 2001, hyaluronidase was classified by FDA as a drug of shortage. In 2004, two hyaluronidase preparations were approved by the FDA — sheep-type hyaluronidase (Vitrase) by ISTA Pharmaceuticals and bovine-type hyaluronidase (Amphadase) by amphasar Pharmaceuticals. In 2005, the FDA approved 2 new applications for hyaluronidase formulations on the market, namely purified bovine testicular hyaluronidase (Hydase) developed by PrimaPharm corporation and recombinant human hyaluronidase (Hylenex) developed by Halozyme pharmaceuticals, inc. Of the five approved hyaluronidases, only Hylenex is the genetically engineered recombinant human hyaluronidase, and the other four are all animal-derived extracts. Due to the well-known problems of raw material sources and the animal pollution risks, the three animal-derived products are stopped in sequence. The current commercial product only leaves the two types of the ovine hyaluronidase Vitrase and the recombinant human hyaluronidase Hylenex.
The recombinant human hyaluronidase Hylenex of the American Halozyme company is a product which is obtained by adopting the recombinant DNA technology to express in CHO cells with high efficiency and high purification, and has the advantages of high purity, low immunogenicity and the like, thereby being widely applied by quickly replacing hyaluronidase extracted from animals. The hyaluronidase is used together with other injection drugs clinically to increase the absorption and dispersion of the latter, and can be used for subcutaneous infusion, promoting the dissipation of local edema or hematoma after operation and trauma and subcutaneous urethrography (improving the reabsorption of contrast agent barium sulfate). Hyaluronidase is also often used in conjunction with local anesthetics during ophthalmic surgery to accelerate the onset of the anesthetic. In addition, the company of the global biopharmaceutical huge headings such as Roche, Qiangsheng and the like combines the recombinant human hyaluronidase Hylenex with a plurality of antibody products with the global sales of more than 50 billion dollars under the flag thereof for tumor treatment, and replaces the expensive antibody administration mode from the traditional intravenous infusion to subcutaneous injection, thereby greatly simplifying the treatment scheme of tumor patients and greatly reducing the cost of the patients and medical systems.
The hyaluronidase widely used in the market is a liquid preparation, the effective component of the liquid preparation is recombinant human hyaluronidase, the rest components are 8.5mg of sodium chloride, 1.4mg of disodium hydrogen phosphate, 1mg of human serum albumin, 1.5mg of L-methionine and 0.2mg of Tween 80 per milliliter, and the shelf life of the product is 24 months. The preparation has the disadvantages of poor activity stability of hyaluronidase in liquid preparation, and inconvenient transportation, storage and use. More importantly, in order to maintain the activity of the enzyme, human serum albumin is used in the liquid preparation, and the human serum albumin is not only high in cost, but also derived from blood plasma and high in risk of infection by pathogens.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a recombinant human hyaluronidase freeze-dried preparation, and a preparation method and application thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
in one aspect, the present invention provides a recombinant human hyaluronidase lyophilized formulation comprising the following components, calculated as 10000 counts:
the recombinant human hyaluronidase freeze-dried preparation comprises 1400000-500000000 IU of recombinant human hyaluronidase, such as 1400000IU, 1500000IU, 1800000IU, 1700000IU, 1800000IU, 1900000IU, 2000000IU, 3000000IU, 5000000IU, 8000000IU, 10000000IU, 50000000IU, 80000000IU, 100000000IU, 300000000IU or 500000000IU calculated by 10000 counts.
The recombinant human hyaluronidase freeze-dried preparation of the present invention comprises 5 to 10g of a buffer, for example, 5g, 5.3g, 5.5g, 5.8g, 6g, 6.3g, 6.5g, 6.8g, 7g, 7.2g, 7.5g, 7.8g, 8g, 8.3g, 8.5g, 8.8g, 9g, 9.2g, 9.5g, 9.8g or 10g, in 10000 counts.
The recombinant human hyaluronidase freeze-dried preparation comprises 60-180 g of cryoprotectant, such as 60g, 65g, 70g, 80g, 90g, 100g, 110g, 120g, 130g, 140g, 150g, 160g, 170g or 180g, calculated by 10000 counts.
The recombinant human hyaluronidase freeze-dried preparation comprises 180-300 g of excipients, such as 180g, 185g, 190g, 195g, 200g, 210g, 220g, 230g, 240g, 250g, 260g, 270g, 280g, 290g or 300g calculated by 10000 counts.
The recombinant human hyaluronidase freeze-dried preparation comprises 5-12 g of enzyme activity protective agent, such as 5g, 6g, 7g, 8g, 9g, 10g, 11g or 12g calculated by 10000 counts.
The freeze-dried preparation of recombinant human hyaluronidase of the present invention comprises 0.3-5 g of surfactant, such as 0.3g, 0.4g, 0.5g, 0.7g, 0.9g, 1g, 1.3g, 1.5g, 1.8g, 2g, 2.2g, 2.5g, 2.8g or 3g, calculated on 10000 counts.
Preferably, in the present invention, the recombinant human hyaluronidase is purified from cell supernatant expressed by CHO.
Preferably, the purity of the recombinant human hyaluronidase is more than 95%, and the specific activity is more than 100000 IU/mg.
In the present invention, the buffer is a phosphate buffer.
Preferably, the cryoprotectant is any one or a combination of at least two of sucrose, trehalose, maltose or lactose, preferably sucrose and/or trehalose.
Preferably, the excipient is mannitol and/or glycine, preferably mannitol.
Preferably, the enzyme activity protective agent is any one or a combination of at least two of sodium chloride, calcium chloride and disodium ethylene diamine tetraacetate, and the combination of the calcium chloride and the disodium ethylene diamine tetraacetate is preferred.
Preferably, the content of calcium chloride in the lyophilized preparation of recombinant human hyaluronidase is 1.2-2.4g, such as 1.2g, 1.3g, 1.5g, 1.7g, 1.9g, 2g, 2.1g, 2.2g, 2.3g or 2.4g, and the content of disodium edetate is 4.8-6.0g, such as 4.8g, 4.9g, 5g, 5.2g, 5.4g, 5.6g, 5.8g, 5.9g or 6g, calculated on 10000 counts.
Preferably, the surfactant is any one or a combination of at least two of polysorbate 20, polysorbate 80 or triton x-100, preferably polysorbate 20 and/or polysorbate 80.
Preferably, the lyophilized preparation is dissolved in water for injection and then used for subcutaneous or intravenous injection.
In another aspect, the present invention provides a method for preparing a lyophilized formulation of recombinant human hyaluronidase as described in the first aspect, the method comprising the steps of:
A. adding the recombinant human hyaluronidase, a buffering agent, a cryoprotectant, an excipient, an enzyme activity protectant and a surfactant into water, and uniformly mixing to prepare a recombinant human hyaluronidase liquid preparation;
B. and D, subpackaging the recombinant human hyaluronidase liquid preparation obtained in the step A, and freeze-drying the subpackaged preparation to obtain the recombinant human hyaluronidase freeze-dried preparation.
Preferably, the freeze-drying process is:
(1) pre-freezing at-2 deg.C to-8 deg.C, such as-2 deg.C, -3 deg.C, -4 deg.C, -5 deg.C, -6 deg.C, -7 deg.C or-8 deg.C, for 0.5-1 h, such as 0.5h, 0.6h, 0.7h, 0.8h, 0.9h or 1 h;
(2) pre-freezing for 2-4 h, such as 2h, 2.2h, 2.4h, 2.6h, 2.8h, 3h, 3.3h, 3.5h, 3.7h, 3.9h or 4h at-35-40 ℃ environment, such as-35 ℃, -36 ℃, -37 ℃, -38 ℃, -39 ℃ or-40 ℃;
(3) drying for 15-25 h, such as 15h, 16h, 17h, 18h, 19h, 20h, 21h, 23h, 24h or 25h in an environment of-15 ℃ to-30 ℃, such as-20 ℃, 21 ℃, 22 ℃, 23 ℃, 24 ℃, 25 ℃, 26 ℃, 27 ℃, 28 ℃, 29 ℃ or-30 ℃, 10-20 mbar, such as 10mbar, 11mbar, 12mbar, 13mbar, 14mbar, 15mbar, 16mbar, 17mbar, 18mbar, 19mbar or 20 mbar;
(4) drying at-5 deg.C to 10 deg.C, such as-5 deg.C, -4 deg.C, -3 deg.C, -2 deg.C, -1 deg.C, 0 deg.C, 1 deg.C, 2 deg.C, 3 deg.C, 4 deg.C, 5 deg.C, 6 deg.C, 7 deg.C, 8 deg.C, 9 deg.C or 10 deg.C to 20mbar, such as 10mbar, 11mbar, 12mbar, 13mbar, 14mbar, 15mbar, 16mbar, 17mbar, 18mbar, 19mbar or 20mbar, for 0.5 to 3 hours, such as 0.5 hour, 0.7 hour, 0.9 hour, 1 hour, 1.3 hour, 1.5 hour, 1.8 hour, 2 hours, 2.2 hours, 2.4 hours, 2.6 hours, 2.8 hours or 3 hours;
(5) drying for 5-15 h, such as 5h, 6h, 7h, 8h, 9h, 10h, 11h, 12h, 13h, 14h or 15h in an environment of 15-30 ℃, such as 15 ℃, 16 ℃, 17 ℃, 18 ℃, 20 ℃, 22 ℃, 24 ℃, 26 ℃, 28 ℃, 29 ℃ or 30 ℃ under 10-20 mbar, such as 10mbar, 11mbar, 12mbar, 13mbar, 14mbar, 15mbar, 16mbar, 17mbar, 18mbar or 20 mbar.
On the other hand, the invention provides the application of the recombinant human hyaluronidase freeze-dried preparation in preparing medicines for promoting dissipation of local edema or hematoma after operation and trauma, promoting infiltration of local anesthetics, relieving pain at injection sites or accelerating absorption of hypodermic or intramuscular injection liquid medicines.
Compared with the prior art, the invention has the following beneficial effects:
the freeze-dried preparation can maintain the stability of hyaluronidase at normal temperature to the maximum extent, is convenient to store, transport and use, does not contain human serum albumin, reduces the risk of pathogen infection, has non-toxic and safe components, has high safety, and can be clinically used for promoting dissipation of local edema or hematoma after operation and trauma, promoting infiltration of local anesthetics, relieving pain of injection parts, accelerating the absorption of subcutaneous injection or intramuscular injection liquid medicine and other indications.
Drawings
FIG. 1 is a graph showing the stability of the lyophilized formulation prepared in example 1;
FIG. 2 is a graph showing the stability of the lyophilized formulation prepared in example 2;
FIG. 3 is a graph showing the stability of the lyophilized formulation prepared in example 3;
fig. 4 is a stability profile of the lyophilized formulation prepared in example 4.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
Example 1
The recombinant human hyaluronidase is obtained by adopting CHO cell suspension culture, and is gradually expanded to the production of a 30L reactor scale through shaking culture. CHO cells grow in a serum-free culture medium independently developed by the company, are produced in a feeding and feeding culture mode, and are selected to control feeding by the serum-free feeding culture medium independently developed by the company; when the culture is carried out for 3 to 4 days, the amount of the supplemented culture medium added into the bioreactor every day is 2 to 5 percent of the actual culture volume in the bioreactor. The culture temperature is controlled at 35-37 deg.C, and 10% Na is supplemented2CO3And CO2Controlling the pH value to 7.0; controlling the aeration quantity of the reactor to be 0.015-0.15 vvm; the rotating speed is controlled to be 80-150 rpm; the dissolved oxygen value is controlled at 20-40%. In thatSampling every day during the cell culture process, and monitoring temperature, pH, glucose concentration, lactic acid concentration, osmolality and protein expression; when the CHO cell survival rate is lower than 80% or the culture period reaches 14-20 days, the culture is finished.
And (3) carrying out deep filtration, anion chromatography, affinity chromatography, hydrophobic chromatography, cation chromatography and ultrafiltration liquid change on the supernatant of the recombinant human hyaluronidase to obtain the hyaluronidase with the purity of more than 99% and the specific activity of 100000 IU/mg.
Dissolving 1800000IU of purified hyaluronidase and the buffer, cryoprotectant, excipient, enzyme activity protectant and surfactant shown in Table 1 with water for injection, fixing volume to 6000mL, packaging 10000 pieces per piece of the solution with volume of 0.6mL, and lyophilizing according to the lyophilization procedure shown in Table 2.
TABLE 1
TABLE 2
| Procedure for the preparation of the | Set sheet temperature (. degree. C.) | Retention time (hr) | Set vacuum degree (mbar) |
| (1) Prefreezing | -5 | 1.0 | |
| (2) Prefreezing | -40 | 3 | |
| (3) Drying | -25 | 19.5 | 15 |
| (4) |
0 | 2.0 | 15 |
| (5) Drying | 25 | 8.5 | 15 |
From each set of A, B, C, D, E, F samples obtained by lyophilization, a spot check was performed, and the shape and the water content of the spot check samples were measured, and the results are shown in Table 3.
TABLE 3
The liquid preparation and the sample for spot-test were placed in an incubator at 40 ℃ and the stability of the lyophilized preparation was compared with that of the liquid preparation (8.5 mg sodium chloride, 1.4mg disodium hydrogenphosphate, 1mg human serum albumin, 1.5mg L-methionine, 0.2mg Tween 80 per ml), and the results are shown in FIG. 1.
As can be seen from FIG. 1, A, B, C, D, E, F lyophilized formulations all had better stability than liquid formulations. In order to keep the protein stable, the cryoprotectant in the lyophilized preparation can be selected to be 10000 counts, and the frozen preparation contains 60g-180g of sucrose or trehalose.
Example 2
In this example, 1800000IU of recombinant human hyaluronidase, and the buffer, cryoprotectant, excipient, enzyme activity protectant and surfactant shown in table 4 were dissolved in water for injection, and the volume was adjusted to 6000mL, and 10000 pieces were dispensed per 0.6 mL/piece, and lyophilized according to the lyophilization procedure shown in table 2.
TABLE 4
| G | H | I | |
| Hyaluronidase | 1800000IU | 1800000IU | 1800000IU |
| Tween 20 | 1.2g | 1.2g | 1.2g |
| Mannitol | 180g | 240g | 300g |
| Sucrose | 120g | 120g | 120g |
| Disodium hydrogen phosphate | 8.4g | 8.4g | 8.4g |
| Ethylenediaminetetraacetic acid disodium salt | 5.4g | 5.4g | 5.4g |
| Calcium chloride | 1.8g | 1.8g | 1.8g |
From each set of G, H, I samples obtained by lyophilization, a spot check was performed, and the shape and the water content of the spot check samples were measured, and the results are shown in Table 5.
TABLE 5
The liquid preparation and the sample for spot-test were placed in an incubator at 40 ℃ and the stability of the lyophilized preparation was compared with that of the liquid preparation (8.5 mg sodium chloride, 1.4mg disodium hydrogenphosphate, 1mg human serum albumin, 1.5mg L-methionine, 0.2mg Tween 80 per ml), and the results are shown in FIG. 2.
As can be seen from FIG. 2, G, H, I lyophilized preparation has better stability than liquid preparation, and in order to keep protein stable, the lyophilized preparation has 10000 excipients, and the frozen preparation contains 180-300 g mannitol.
Example 3
In this example, 1800000IU of recombinant human hyaluronidase, and the buffer, cryoprotectant, excipient, enzyme activity protectant, and surfactant shown in table 6 were dissolved in water for injection, and the volume was adjusted to 6000mL, and 10000 pieces were dispensed per 0.6 mL/piece, and lyophilized according to the lyophilization procedure shown in table 2.
TABLE 6
From each set of J, K, L, M, N, O samples obtained by lyophilization, a spot check was performed, and the shape and the water content of the spot check samples were measured, and the results are shown in Table 7.
TABLE 7
The liquid preparation and the sample for spot-test were placed in an incubator at 40 ℃ and the stability of the lyophilized preparation was compared with that of the liquid preparation (8.5 mg sodium chloride, 1.4mg disodium hydrogenphosphate, 1mg human serum albumin, 1.5mg L-methionine, 0.2mg Tween 80 per ml), and the results are shown in FIG. 3.
As can be seen from FIG. 3, J, K, L, M, N, O lyophilized preparation has better stability than liquid preparation, and in order to keep protein stable, the surfactant in the lyophilized preparation can be selected to be calculated by 10000 counts, and the frozen preparation contains 0.3g-3.0g of Tween 20 or Tween 80.
Example 4
Different doses of hyaluronidase, as well as the buffer, cryoprotectant, excipient, enzyme activity protectant and surfactant shown in table 8 were dissolved in water for injection, the volume was adjusted to 6000mL, and 10000 doses of the preparation were dispensed per 0.6mL, lyophilized, and lyophilized according to the lyophilization procedure shown in table 2.
TABLE 8
From each set of P, Q, R, S samples obtained by lyophilization, a sample was sampled, and the shape and water content of the sampled samples were measured, and the results are shown in Table 9.
TABLE 9
The stability of the four lyophilized formulations of different hyaluronidase doses in a 40 ℃ incubator was compared to the stability of the higher and lower hyaluronidase doses, and the results are shown in figure 4.
As can be seen from fig. 4, Q, R, S three high dose lyophilized formulations were as stable as the P low dose lyophilized formulation. The total activity of the hyaluronidase in the freeze-dried preparation is calculated by 10000 counts, and can be 1400000-500000000 IU.
Therefore, in the invention, 10000 freeze-dried preparations are prepared by using 1400000-2000000 IU of recombinant human hyaluronidase, 5-10 g of buffer, 60-180 g of cryoprotectant, 180-300 g of excipient, 5-12 g of enzyme activity protectant and 0.3-5 g of surfactant, and have high stability and are convenient to store, transport and use.
The applicant states that the recombinant human hyaluronidase lyophilized preparation of the present invention and the preparation method thereof are illustrated by the above examples, but the present invention is not limited to the above examples, i.e., it is not meant that the present invention must be implemented by the above examples. It should be understood by those skilled in the art that any modification of the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
Claims (7)
1. The recombinant human hyaluronidase freeze-dried preparation is characterized by consisting of 10000 counts:
1800000-500000000 IU of recombinant human hyaluronidase
Buffer 8.4g
60-180 g of cryoprotectant
180-300 g of excipient
Enzyme activity protective agent 7.2g
0.3-3 g of surfactant;
the purity of the recombinant human hyaluronidase is more than 99 percent, and the specific activity is 100000 IU/mg;
the buffering agent is disodium hydrogen phosphate, and the cryoprotectant is sucrose or trehalose; the excipient is mannitol, the enzyme activity protective agent is a combination of calcium chloride and disodium ethylene diamine tetraacetate, and the surfactant is polysorbate 20 and/or polysorbate 80.
2. The lyophilized formulation of recombinant human hyaluronidase of claim 1, wherein the recombinant human hyaluronidase is purified from a cell supernatant expressed by CHO.
3. The lyophilized preparation of recombinant human hyaluronidase according to claim 1, wherein the content of calcium chloride in the lyophilized preparation of recombinant human hyaluronidase is 1.2-2.4g and the content of disodium edetate is 4.8-6.0g, calculated as 10000 counts.
4. The lyophilized formulation of recombinant human hyaluronidase of claim 1 that is dissolved in water for injection and then administered subcutaneously or intravenously.
5. The method for preparing the lyophilized formulation of recombinant human hyaluronidase according to any one of claims 1-4, wherein the method includes the steps of:
A. adding the recombinant human hyaluronidase, a buffering agent, a cryoprotectant, an excipient, an enzyme activity protectant and a surfactant into water, and uniformly mixing to prepare a recombinant human hyaluronidase liquid preparation;
B. and D, subpackaging the recombinant human hyaluronidase liquid preparation obtained in the step A, and freeze-drying the subpackaged preparation to obtain the recombinant human hyaluronidase freeze-dried preparation.
6. The method of claim 5, wherein the freeze-drying process is:
(1) pre-freezing for 0.5-1 h at the temperature of-2 ℃ to-8 ℃;
(2) pre-freezing for 2-4 h at-35 to-40 ℃;
(3) drying for 15-25 h at-15 to-30 ℃ under the environment of 10-20 mbar;
(4) drying for 0.5-3 h at-5-10 ℃ under the environment of 10-20 mbar;
(5) drying for 5-15 h at 15-30 ℃ under the environment of 10-20 mbar.
7. Use of the lyophilized formulation of recombinant human hyaluronidase according to any one of claims 1-4 in the manufacture of a medicament for promoting dissipation of local edema or hematoma following surgery and trauma, promoting infiltration of local anesthetics, reducing pain at the site of injection, or accelerating absorption of subcutaneous or intramuscular injection solutions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610081945.XA CN105727267B (en) | 2016-02-05 | 2016-02-05 | Recombinant human hyaluronidase freeze-dried preparation and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610081945.XA CN105727267B (en) | 2016-02-05 | 2016-02-05 | Recombinant human hyaluronidase freeze-dried preparation and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105727267A CN105727267A (en) | 2016-07-06 |
| CN105727267B true CN105727267B (en) | 2020-05-26 |
Family
ID=56241921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610081945.XA Active CN105727267B (en) | 2016-02-05 | 2016-02-05 | Recombinant human hyaluronidase freeze-dried preparation and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105727267B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0408116B1 (en) | 2003-03-05 | 2022-09-20 | Halozyme, Inc | POLYMER-CONJUGATED SOLUBLE HYALURONIDASE POLYPEPTIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SOLUBLE PH20 POLYPEPTIDES, THEIR USES AND PREPARATION PROCESS, AND NUCLEIC ACIDS ENCODING SOLUBLE HYALURONIDASE POLYPEPTIDES |
| EP4017524A4 (en) * | 2019-10-15 | 2022-09-21 | Standard of Care Corporation | Compositions comprising hyaluronidase and/or collagenase and/or 4-methylumbelliferone (4-mu) and methods of treatment using same |
| CN114250212A (en) * | 2021-12-14 | 2022-03-29 | 华熙生物科技股份有限公司 | Hyaluronidase freeze-dried preparation and preparation method thereof |
| CN114010528B (en) * | 2021-12-20 | 2023-09-15 | 广州栋方生物科技股份有限公司 | Recombinant human collagen freeze-dried powder and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104768535A (en) * | 2012-11-05 | 2015-07-08 | 株式会社Bmi韩国 | Stabilizer for hyaluronidase and liquid formulation comprising hyaluronidase |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100580082C (en) * | 2003-03-14 | 2010-01-13 | 河北以岭医药研究院有限公司 | Lyophylization preparation of recombinant staphylokinase, its preparing method and application |
| EP3130347B1 (en) * | 2011-12-30 | 2019-09-18 | Halozyme, Inc. | Ph20 polypeptide variants, formulations and uses thereof |
| CN103468662A (en) * | 2013-09-29 | 2013-12-25 | 惠觅宙 | Recombined human hyaluronidase, production and purification method and preparations thereof, use method and application |
-
2016
- 2016-02-05 CN CN201610081945.XA patent/CN105727267B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104768535A (en) * | 2012-11-05 | 2015-07-08 | 株式会社Bmi韩国 | Stabilizer for hyaluronidase and liquid formulation comprising hyaluronidase |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105727267A (en) | 2016-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105727267B (en) | Recombinant human hyaluronidase freeze-dried preparation and preparation method and application thereof | |
| US6875441B2 (en) | Composition for delivery of hematopoietic growth factor | |
| CN107012119B (en) | Method for extracting immune cells from bone marrow | |
| CN101143212B (en) | Recombination human acidic mechanocyte growth factor temperature sensitive type gel preparation and preparation method thereof | |
| EA032336B1 (en) | Stable aqueous immunoglobulin composition and method of stabilization thereof | |
| EP2628484B1 (en) | Platelet-rich plasma compositions | |
| CN110613680A (en) | Preparation method of gel preparation for wound | |
| CN101095950A (en) | Hydrophobia vaccine freezing drying preparations for stable human beings and the preparations thereof | |
| AU2014338863A1 (en) | Stable formulation of insulin glulisine | |
| CA2378949C (en) | Growth hormone formulations | |
| CN104906576B (en) | For hypodermic high concentration anti-VEGF antibody preparaton | |
| CN101693016B (en) | Universal pharmaceutical formulation for recombined human serum albumin fusion proteins for injection | |
| CN1802171A (en) | Stable, aqueous solution of human erythropoietin, not containing serum albumin | |
| EP3848058A1 (en) | Viral inactivated biological mixture | |
| CN111588859B (en) | Freeze-drying protective agent and application thereof, freeze-dried seedling and preparation method thereof | |
| CN105308173A (en) | A pharmaceutical composition for stimulation of angiogenesis | |
| CN102973922A (en) | Application of fusion protein | |
| EP1623723A2 (en) | Stable gene formulations | |
| TW201900192A (en) | Composition and method for live attenuated alpha virus formula | |
| KR100954311B1 (en) | Separate type medical material | |
| CN113797318B (en) | Interferon composition and preparation method and application thereof | |
| CN110755451B (en) | Mesenchymal stem cell composition for treating osteoarthritis and application thereof | |
| CN110755452A (en) | Use of stem cells for treating osteoarthritis | |
| CN114681594A (en) | Application of recombinant human hyaluronidase preparation | |
| JP7321142B2 (en) | Pharmaceutical composition, package and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210812 Address after: 215123 Room 401, C13 floor, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou, Jiangsu Province Patentee after: SUZHOU KANGJU BIOLOGICAL TECHNOLOGY Co.,Ltd. Patentee after: Shanghai Baoji Pharmaceutical Co.,Ltd. Address before: 215123 room 301A, C13 / F, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou City, Jiangsu Province Patentee before: SUZHOU KANGJU BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a lyophilized preparation of recombinant human hyaluronidase and a preparation method and application thereof Effective date of registration: 20211228 Granted publication date: 20200526 Pledgee: Shanghai Luocun Industrial Co.,Ltd. Pledgor: Shanghai Baoji Pharmaceutical Co.,Ltd. Registration number: Y2021980016793 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221031 Granted publication date: 20200526 Pledgee: Shanghai Luocun Industrial Co.,Ltd. Pledgor: Shanghai Baoji Pharmaceutical Co.,Ltd. Registration number: Y2021980016793 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| CP03 | Change of name, title or address |
Address after: 215123 room 301A, C13 / F, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou City, Jiangsu Province Patentee after: SUZHOU KANGJU BIOLOGICAL TECHNOLOGY Co.,Ltd. Patentee after: Shanghai Baoji Pharmaceutical Co.,Ltd. Address before: 215123 Room 401, C13 floor, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou, Jiangsu Province Patentee before: SUZHOU KANGJU BIOLOGICAL TECHNOLOGY Co.,Ltd. Patentee before: Shanghai Baoji Pharmaceutical Co.,Ltd. |
|
| CP03 | Change of name, title or address |